Jian Chen

Jian Chen

Auto-generated profile, based on publicly available information

Jian Chen

Department of Thyroid and Hernia Surgery, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University , Guangzhou, Guangdong 510080

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 September 2022 in Oncogene
Verified
Journal Article
Closed access
PDF file
JCJian Chen
Jian Chen
LLLu Li
Lu Li
TLTian-Yu Liu
Tian-Yu Liu
HFHuafeng Fu
Huafeng Fu
YLYuan-Hui Lai
Yuan-Hui Lai
YHYulong He
Yulong He

10 March 2025 in Cancer Letters
Verified
Journal Article
Closed access
LXLei Xu
Lei Xu
BDBao Dai
Bao Dai
LZLingyun Zhang
Lingyun Zhang
WCWeijian Chen
Weijian Chen
SRShikuo Rong
Shikuo Rong
ZWZeyu Wu
Zeyu Wu

3 February 2026 in Endocrinology
Verified
Journal Article
Closed access
JCJian Chen
Jian Chen
LXLei Xu
Lei Xu
TLTian-Yu Liu
Tian-Yu Liu
WCWei-Jian Chen
Wei-Jian Chen
BDBao Dai
Bao Dai
ZWZe-Yu Wu
Ze-Yu Wu
Follicular thyroid carcinoma (FTC) is prone to early distant metastasis and has a poor prognosis compared with papillary thyroid carcinoma (PTC). This study aimed to unravel the cellular and molecular mechanisms underlying FTC progression and its transformation into the aggressive anaplastic thyroid carcinoma (ATC). Through single-cell RNA sequencing (scRNA-seq) profiling of 46 739 cells from PTC, follicular variant PTC (FVPTC), relapsed FTC (RFTC), and ATC, we reconstructed a comprehensive molecular trajectory of thyroid carcinoma progression. Our analysis revealed that PTC, FVPTC, and FTC possess distinct yet converging pathways of dedifferentiating into ATC, with FVPTC also able to progress to FTC. In RFTC, we identified a unique cluster of cells exhibiting ATC molecular characteristics. These cells interact with endothelial cells and fibroblasts mainly via the COL9A3-integrin α1β1 complex and may exhibit high metabolic and proliferative potential. UBE2C was identified as a specific marker for this population, which we termed “ATC-like cells.” Functional validation in vitro and in vivo confirmed that UBE2C was markedly upregulated in FTC and was associated with adverse clinical outcomes. Mechanistically, UBE2C promoted cell proliferation and tumor growth, and regulated D-arginine and D-ornithine metabolism, glutathione metabolism, glycerophospholipid metabolism and tryptophan metabolism in FTC. This reveals a previously unrecognized population of ATC-like cells in RFTC marked by high UBE2C expression. UBE2C contributes to FTC progression by enhancing proliferation and modulating key metabolic pathways, suggesting it as both a critical biomarker of aggressive disease and a potential therapeutic target.